Androgenetic Alopecia clinical trials

Explore recruiting androgenetic alopecia clinical trials.

Recruiting androgenetic alopecia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Androgenetic Alopecia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A 6-Month Phase 3, Multicenter, Prospective, Randomized, Double-Blind, Vehicle-Controlled Study, to Evaluate the Efficacy and Safety of Topically Applied Clascoterone (Cortexolone 17α-Propionate) Solution for the Treatment of Androgenetic Alopecia in Males, Followed by a 6-Month Single-Blind Treatment with Clascoterone or Vehicle BID Solution (SCALP 2)

Germany, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase I clinical trial evaluating the safety, tolerability, and absorption of a topical product containing latanoprost acid in healthy participants.

Poland

Human Pharmacology (Phase I)- Other EU CTIS Study details

Randomised, crossover bioavailability clinical trial of oral minoxidil 1 mg, after single and multiple dose administration to healthy volunteers under fasting conditions

Spain

Human Pharmacology (Phase I)- Other EU CTIS Study details

International Phase III, Multi-center, Randomized, Double-blind, Placebo and Active-controlled and Parallel group Clinical Trial to Evaluate the Efficacy and Safety of Oral Minoxidil 1 mg in Female patients with Androgenetic Alopecia.

Portugal, Spain, Germany, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

Androgenetic Alopecia trials by city

Androgenetic Alopecia in Toronto Androgenetic Alopecia in Vancouver Androgenetic Alopecia in Montreal Androgenetic Alopecia in Calgary Androgenetic Alopecia in Edmonton Androgenetic Alopecia in Ottawa Androgenetic Alopecia in Winnipeg Androgenetic Alopecia in Quebec City Androgenetic Alopecia in Hamilton Androgenetic Alopecia in Kitchener Androgenetic Alopecia in London Androgenetic Alopecia in Halifax Androgenetic Alopecia in New York Androgenetic Alopecia in Los Angeles Androgenetic Alopecia in Chicago Androgenetic Alopecia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease